

CBG DROPS

5 -15%



Ingredients: CAPRYLIC/CAPRIC TRIGLYCERIDE,
CANNABIS SATIVA BIOMASS EXTRACT



MCT OIL
Caprylic/capric triglyceride



HEMP EXTRACT
Cannabis sativa L.

CERTIFICATE OF ANALYSIS No.: 2021-6887

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8
1000 Ljubljana, Slovenija

SAMPLE *

CBG DROPS 5% - mct oil



Sample condition: SUITABLE
Sample ID: 2146050
Sample type: Viscous liquid
Batch No.: * DR05021321B

Work order: 2021-105878
Analysis ID: 2021_268
Method ID: PHL_RPC_12C
Method SOP: MET-002-03

Sample received: 18/11/2021
Start of analysis: 18/11/2021
End of analysis: 19/11/2021
Analyst: Karmen Korbar

* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
 CBDV - Cannabidivarin	0.115	0.021	
 CBDA - Cannabidiolic acid	< LOQ	n/a	
 CBGA - Cannabigerolic acid	< LOQ	n/a	
 CBG - Cannabigerol	5.02	0.35	
 CBD - Cannabidiol	0.687	0.069	
 THCV - Tetrahydrocannabivarin	< LOQ	n/a	
 CBN - Cannabinol	< LOQ	n/a	
 CBC - Cannabichromene	0.046	0.010	
 THC - Δ-9-Tetrahydrocannabinol	0.0372	0.0082	
 THCA - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
 8-THC - Δ-8-Tetrahydrocannabinol	< LOQ #	n/a	
 CBL - Cannabicyclol	< LOQ #	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor $k = 2$, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

19/11/2021

Approved by:

mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate


CERTIFICATE OF ANALYSIS No.: 2022-9648

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8
1000 Ljubljana, Slovenija

SAMPLE *

CBG DROPS 10% - mct oil



Sample condition: SUITABLE
Sample ID: 2233047
Sample type: Viscous liquid
Batch No.: * DR10022230A

Work order: 2022-106836
Analysis ID: 2022_188
Method ID: PHL_RPC_12C
Method SOP: MET-LAB-003-02

Sample received: 19/08/2022
Start of analysis: 19/08/2022
End of analysis: 22/08/2022
Analyst: Janez Gerdenc

* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	< LOQ	n/a	_____
CBDA - Cannabidiolic acid	< LOQ	n/a	_____
CBGA - Cannabigerolic acid	< LOQ	n/a	_____
CBG - Cannabigerol	10.18	0.71	████████████████████
CBD - Cannabidiol	1.407	0.070	██████████
THCV - Tetrahydrocannavarin	< LOQ	n/a	_____
CBN - Cannabinol	< LOQ	n/a	_____
Δ⁹-THC - Δ-9-Tetrahydrocannabinol	0.061	0.013	_____
Δ⁸-THC - Δ-8-Tetrahydrocannabinol	< LOQ	n/a	_____
CBL - Cannabicyclol	< LOQ	n/a	_____
CBC - Cannabichromene	0.111	0.019	_____
Δ⁹-THCA - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	_____
CBE - Cannabielsoin	0.073 #	0.020	_____
CBNV - Cannabivarin	< LOQ #	n/a	_____
CBCA - Cannabichromenic acid	< LOQ #	n/a	_____
CBT - Cannabicitran	0.101 #	0.017	_____

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.


The results given herein apply only to the sample as received. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

22/08/2022

Approved by:



mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:



dr. Boštjan Jančar
Chief Technology Officer

End of Certificate


CERTIFICATE OF ANALYSIS No.: 2022-8177

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8
1000 Ljubljana, Slovenija

SAMPLE *

CBG DROPS 15% - mct oil



Sample condition: SUITABLE
Sample ID: 2211048
Sample type: Viscous liquid
Batch No.: * DR15022073A

Work order: 2022-106306
Analysis ID: 2022_061
Method ID: PHL_RPC_12C
Method SOP: MET-002-03

Sample received: 16/03/2022
Start of analysis: 16/03/2022
End of analysis: 17/03/2022
Analyst: Janez Gerdenc

* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
 CBDV - Cannabidivarin	0.322	0.058	
 CBDA - Cannabidiolic acid	< LOQ	n/a	
 CBGA - Cannabigerolic acid	< LOQ	n/a	
 CBG - Cannabigerol	15.0	1.0	
 CBD - Cannabidiol	1.967	0.098	
 THCV - Tetrahydrocannabivarin	< LOQ	n/a	
 CBN - Cannabinol	< LOQ	n/a	
 CBC - Cannabichromene	0.128	0.022	
 THC - Δ-9-Tetrahydrocannabinol	0.090	0.020	
 THCA - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
 8-THC - Δ-8-Tetrahydrocannabinol	< LOQ #	n/a	
 CBL - Cannabicyclol	< LOQ #	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.


The results given herein apply only to the sample as received. **Expanded Uncertainty** was calculated using coverage factor $k = 2$, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:


17/03/2022

Approved by:



mag. Marko Dragan
Analytical Laboratory Manager

Authorized by:



dr. Boštjan Jančar
Chief Technology Officer

End of Certificate